Reference

Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist

Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 5th communication. Hemodynamic effects of valsartan in dog heart failure models. Yamamoto, Shigeru; Hayashi, Naoyuki; Kometani, Motohiko; Nakao, Kenzo (Pharmaceutical Division, Ciba-Geigy Japan Ltd., Takarazuka 665, Japan). Arzneimittel-Forschung, 47(5), 630-634 (English) 1997 Cantor. CODEN: ARZNAD. ISSN: 0004-4172. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Hemodynamic effects of valsartan ((S)-N-valeryl-N-([2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl)valine, CAS 137862-53-4, CGP 48933), a non-peptide angiotensin II type 1 receptor antagonist were examd. in dogs with heart failure induced acutely by coronary artery ligation and chronically by rapid-ventricular pacing. Coronary artery ligation induced decrease in cardiac output and increase in left ventricular end-diastolic pressure. Valsartan at 10 mg/kg i.v. reduced blood pressure, heart rate, left ventricular pressure, left ventricular end-diastolic pressure and total systemic resistance. Similar changes were obsd. with enalaprilat at 0.1 mg/kg i.v. Rapid left ventricular pacing for 2 wk reduced cardiac contractility. Valsartan, administered at a dose of 100 mg/kg/d p.o. for 2 wk, lowered left ventricular end-diastolic pressure. Valsartan reduced preload and afterload in these 2 dog heart failure models.

Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist

Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 4th communication. Improvement of heart failure of rats with myocardial infarction by valsartan. Hayashi, Naoyuki; Fujimura, Yoko; Yamamoto, Shigeru; Kometani, Motohiko; Nakao, Kenzo (Pharmaceutical Division, Ciba-Geigy Japan Ltd., Takarazuka 665, Japan). Arzneimittel-Forschung, 47(5), 625-629 (English) 1997 Cantor. CODEN: ARZNAD. ISSN: 0004-4172. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The hemodynamic effects of valsartan ((S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}valine, CAS 137862-53-4, CGP 48933), a new angiotensin II type 1 receptor antagonist, on rats with myocardial infarction induced by coronary artery ligation was examd. Four weeks after ligation, mean blood pressure, left ventricular pressure and cardiac output decreased, while left ventricular end-diastolic pressure increased in control rats. Left ventricular end-diastolic pressure decreased in rats treated with valsartan at 30 mg/kg/d p.o. for 4 wk. Total systemic resistance decreased in those with enalapril 3 mg/kg/d p.o. and valsartan 30 mg/kg/d p.o. Valsartan and enalaprilat did not affect cardiac functions of isolated intact rat hearts before and after ischemia in Langendorff app. In addn. to hemodynamic effects obsd. in vivo, valsartan at 30 mg/kg p.o. inhibited left ventricular hypertrophy. Valsartan would thus appear to be clin. useful for treating heart failure following myocardial infarction.